Skip to main content Accessibility help
×
Home

New Pharmacotherapeutic Approaches to Obsessive-Compulsive Disorder

  • Martijn Figee (a1) and Damiaan Denys

Abstract

This article summarizes results of all pharmacotherapy trials for obsessive-compulsive disorder (OCD) published from 2006 to 2008 as well as studies on markers for predicting response to treatment and neurobiological changes induced by pharmacotherapy. Results show that recent developments in the treatment of OCD have been modest and primarily involve evidence for the efficacy of escitalopram and other selective serotonin reuptake inhibitors (SSRIs); augmentation with antipsychotics in treatment-refractory patients and combination treatment with D-cycloserine and cognitive-behavioral therapy has also been effective. The efficacy of serotonin-norepinephrine reuptake inhibitors remains inconclusive. Studies on markers of clinical response have shown inconsistent results, however, duration and severity of OCD and the presence of comorbidities can often identify patients at risk for nonresponse. Lastly, successful treatment with an SSRI results in both serotonergic and dopaminergic changes, but more research is necessary in order to define the biological characteristics of responders and nonresponders.

Copyright

Corresponding author

Damiaan Denys, MD, PhD, Academic Medical Centre, University of Amsterdam, PA.2-179, P.O. Box 75867, 1070 AW Amsterdam; Tel: 31-20-8913899; Fax 31-20-8913898; E-mail: d.denys@amc.nl.

References

Hide All
1.American Psychiatric Association. Treatment of Patients With Obsessive-Compulsive Disorder. Available at: www.psychiatryonline.com/pracGuide/pracGuideChapToc_10.aspx. Accessed January 30, 2009.
2.Denys, D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am. 2006;29(2):553–84, xi.
3.Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252260.
4.Wilhelm, S, Buhlmann, U, Tolin, DF, et al.Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165(3):335341.
5.Storch, EA, Merlo, LJ, Bengtson, M, et al.D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(4):230237.
6.Kushner, MG, Kim, SW, Donahue, C, et al.D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62(8):835838.
7.Stein, DJ, Andersen, EW, Tonnoir, B, Fineberg, N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007;23(4):701711.
8.Stein, DJ, Andersen, EW, Overo, KF. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev Bras Psiquiatr. 2007;29(4):303307.
9.Fineberg, NA, Tonnoir, B, Lemming, O, Stein, DJ. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2007;17(6-7):430439.
10.Rabinowitz, I, Baruch, Y, Barak, Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008;23(1):4953.
11.Onder, E, Tural, U, Gokbakan, M. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder? Eur Arch Psychiatry Clin Neurosci. 2008;258(6):319323.
12.Galvão-de Almeida, A, Quarantini, LC, Góis, CR, et al.Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. CNS Spectr. 2007;12(7):519524.
13.Saxena, S, Brody, AL, Maidment, KM, Baxter, LR Jr.Paroxetine treatment of compulsive hoarding. J Psychiatr Res. 2007;41(6):481487.
14.Moreno, FA, Wiegand, CB, Taitano, EK, Delgado, PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):17351740.
15.Shim, GS, Kang, DH, Kwon, JS. High-dose escitalopram treatment in patients with obsessive-compulsive disorder: a naturalistic case series. J Clin Psychopharmacol. 2008;28(1):108110.
16.Desarkar, P, Das, A, Nizamie, SH. Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol. 2007;27(3):305306.
17.Mouaffak, F, Gallarda, T, Baylé, FJ, Olié, JP, Baup, N. Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. J Clin Psychopharmacol. 2007;27(2):237238.
18.Soomro, GM, Altman, D, Rajagopal, S, Oakley-Browne, M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765.
19.Fineberg, NA, Pampaloni, I, Pallanti, S, Ipser, J, Stein, DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(6):313322.
20.Maina, G, Pessina, E, Albert, U, Bogetto, F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18(5):364372.
21.Amiaz, R, Fostick, L, Gershon, A, Zohar, J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008;18(6):455461.
22.Simpson, HB, Foa, EB, Liebowitz, MR, et al.A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165(5):621630.
23.Van Ameringen, M, Mancini, C, Patterson, B, Bennett, M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety. 2006;23(1):15.
24.Tundo, A, Salvati, L, Busto, G, Di Spigno, D, Falcini, R. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. J Clin Psychiatry. 2007;68(10):15521556.
25.Dell’osso, B, Mundo, E, Marazziti, D, Altamura, AC. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008;22(2):210213.
26.Sarkar, R, Klein, J, Kruger, S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2008;197(4):687688.
27.Yang, KC, Su, TP, Chou, YH. Effectiveness of aripiprazole in treating obsessive compulsive symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):585586.
28.da Rocha, FF, Correa, H. Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):15501551.
29.Friedman, S, Abdallah, TA, Oumaya, M, Rouillon, F, Guelfi, JD. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2007;68(6):972973.
30.Luis, BS, Black, DW. A case of obsessive-compulsive disorder responding to duloxetine. Prim Care Companion J Clin Psychiatry. 2007;9(3):234235.
31.Denys, D, Fineberg, N, Carey, PD, Stein, DJ. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry. 2007;61(3):412414.
32.Fineberg, NA, Gale, TM, Sivakumaran, T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol. 2006;20(1):97103.
33.Bloch, MH, Landeros-Weisenberger, A, Kelmendi, B, Coric, V, Bracken, MB, Leckman, JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622632.
34.Stein, DJ, Ipser, JC, Baldwin, DS, Bandelow, B. Treatment of obsessive-compulsive disorder. CNS Spectr. 2007;12(2 suppl 3):2835.
35.Goodman, WK, Price, LH, Rasmussen, SAet al.The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):10061011.
36.Goodman, WK, Price, LH, Rasmussen, SAet al.The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46(11):10121016.
37.Guy, W. Clinical global impressions (CGI) scale. In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:100102.
38.Tolin, DF, Abramowitz, JS, Diefenbach, GJ. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale. J Clin Psychiatry. 2005;66(12):15491557.
39.Sánchez, C, Bøgesø, KP, Ebert, B, Reines, EH, Braestrup, C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl ). 2004;174(2):163176.
40.Fineberg, NA, Gale, TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005;8(1):107129.
41.Denys, D, Van Nieuwerburgh, F, Deforce, D, Westenberg, HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007;68(5):747753.
42.Goisman, RM, Rogers, MP, Steketee, GS, Warshaw, MG, Cuneo, P, Keller, MB. Utilization of behavioral methods in a multicenter anxiety disorders study. J Clin Psychiatry. 1993;54(6):213218.
43.Foa, EB, Kozak, MJ, Steketee, GS, McCarthy, PR. Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy. Br J Clin Psychol. 1992;31 (Pt. 3):279292.
44.Franklin, ME, Abramowitz, JS, Kozak, MJ, Levitt, JT, Foa, EB. Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Consult Clin Psychol. 2000;68(4):594602.
45.Baldwin, DS, Anderson, IM, Nutt, DJ, et al.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567596.
46.Koran, LM, Hanna, GL, Hollander, E, Nestadt, G, Simpson, HB, and the American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7 suppl):553.
47.Hewlett, WA, Schmid, SP, Salomon, RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003;64(9):10251030.
48.Lundberg, S, Carlsson, A, Norfeldt, P, Carlsson, ML. Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(7):11951199.
49.Pasquini, M, Garavini, A, Biondi, M. Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):157159.
50.Taylor, LH, Kobak, KA. An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000;61(8):575578.
51.Strassman, RJ, Qualls, CR, Uhlenhuth, EH, Kellner, R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51(2):98108.
52.Pallanti, S, Hollander, E, Bienstock, C, et al.Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5(2):181191.
53.Ipser, JC, Carey, P, Dhansay, Y, Fakier, N, Seedat, S, Stein, DJ. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD005473.
54.Kordon, A, Wahl, K, Koch, N, et al.Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):550554.
55.Connor, KM, Payne, VM, Gadde, KM, Zhang, W, Davidson, JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66(1):4951.
56.Fineberg, NA, Stein, DJ, Premkumar, P, et al.Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol. 2006;21(6):337343.
57.Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382389.
58.Hamilton, M. Hamilton anxiety rating scale (HARS). In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:554557.
59.Insel, TR, Pickar, D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry. 1983;140(9):12191220.
60.Coric, V, Milanovic, S, Wasylink, S, Patel, P, Malison, R, Krystal, JH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl). 2003;167(2):219220.
61.Eddy, KT, Dutra, L, Bradley, R, Westen, D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24(8):10111030.
62.Foa, EB, Liebowitz, MR, Kozak, MJ, et al.Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151161.
63.Walker, DL, Ressler, KJ, Lu, KT, Davis, M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22(6):23432351.
64.Richardson, R, Ledgerwood, L, Cranney, J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem. 2004;11(5):510516.
65.Woods, AM, Bouton, ME. D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. Behav Neurosci. 2006;120(5):11591162.
66.Ressler, KJ, Rothbaum, BO, Tannenbaum, L, et al.Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):11361144.
67.Hofmann, SG, Meuret, AE, Smits, JA, et al.Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63(3):298304.
68.Norberg, MM, Krystal, JH, Tolin, DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):11181126.
69.Quartermain, D, Mower, J, Rafferty, MF, Herting, RL, Lanthorn, TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;257(1-2):712.
70.Hamilton, M. Hamilton rating scale for depression (HAM-D). In: Rush, AJ, Pincus, HA, First, MB, et al. eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:526529.
71.Baxter, LR Jr, Schwartz, JM, Bergman, KS, et al.Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49(9):681689.
72.Sumitani, S, Harada, M, Kubo, H, Ohmori, T. Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients. Psychiatry Res. 2007;154(1):8592.
73.Barker, PB. N-acetyl aspartate--a neuronal marker? Ann Neurol. 2001;49(4):423424.
74.Ebert, D, Speck, O, Konig, A, Berger, M, Hennig, J, Hohagen, F. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res. 1997;74(3):173176.
75.Rosenberg, DR, MacMaster, FP, Keshavan, MS, Fitzgerald, KD, Stewart, CM, Moore, GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):10961103.
76.Hurley, RA, Saxena, S, Rauch, SL, Hoehn-Saric, R, Taber, KH. Predicting treatment response in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2002;14(3):249253.
77.Moresco, RM, Pietra, L, Henin, M, et al.Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology. 2007;32(1):197205.
78.Kim, CH, Cheon, KA, Koo, MS, et al.Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology. 2007;55(3-4):156162.
79.Pogarell, O, Poepperl, G, Mulert, C, et al.SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacol. 2005;15(5):521524.
80.Zitterl, W, Aigner, M, Stompe, T, et al.Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology. 2008;33(13):31263134.

Related content

Powered by UNSILO

New Pharmacotherapeutic Approaches to Obsessive-Compulsive Disorder

  • Martijn Figee (a1) and Damiaan Denys

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.